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2013 (5) suggest that many clinicians, including
noncardiovascular specialists, will encounter a patient
on, or will themselves prescribe, an oral anticoagulant.
Clinicians should familiarize themselves with these
effective yet potentially harmful agents.
Despite their greater cost, DOACs may soon over-
take warfarin as the predominant oral anticoagulant
prescribed to Medicaid beneﬁciaries. Due to the
structure of the American health care system,
the actual out-of-pocket expense to a patient varies
widely and represents a fraction of the drug’s
wholesale price. Although warfarin copays are
likely less expensive than DOAC copays, this differ-
ence does not appear to preclude DOAC use. More-
over, we speculate that rivaroxaban’s once-daily
administration and apixaban’s favorable safety pro-
ﬁle drive clinician preferences for these DOACs.
Relative underuse of dabigatran may be attributable
to its gastrointestinal intolerance, whereas edox-
aban’s underuse may be due to its unusual dosing
(contraindicated if creatinine clearance >95 ml/min
in atrial ﬁbrillation) and being last to market.
This analysis lacked patient-level and cost data.
Thus, we could not differentiate between new and
existing users of oral anticoagulants or the charac-
teristics of such persons. Nevertheless, oral antico-
agulant use, primarily due to DOAC use, is increasing
among Medicaid beneﬁciaries.
In conclusion, we found that DOACs have begun to
displace warfarin as the predominantly used oral
anticoagulant among patients with limited ﬁnancial
resources despite the higher overall cost of these
agents.
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More Genes for Thoracic
Aortic Aneurysms
and Dissections
In the current genomics era, technological advances
have led to the identiﬁcation of an increasing number
of gene–disease associations. In a recent issue of the
Journal, Renard et al. (1) assessed and clinically
validated genes that may predispose to syndromic
or nonsyndromic forms of heritable thoracic aortic
aneurysm and dissection (HTAAD), classifying a
total of 53 genes into 5 categories (from “deﬁnitive/
strong” to “no evidence”). Such expert-curated gene
categories and panels, which need to be updated
regularly, facilitate the challenging interpretation of
sequence variants detected by high-throughput
clinical sequencing (2). To update the study of
Renard et al. (1), we propose to extend the category
“recent genes” by AEBP1, LMOD1, and LTBP3
(Table 1), because heterozygous (LMOD1) or biallelic
(AEBP1 and LTBP3) pathogenic sequence variants in
these genes have very recently been reported in
aortic aneurysm cases with syndromic or
nonsyndromic presentations (3–5). Furthermore, we
propose to include additional genes, which are, like
these 3 recent and many of the 53 curated genes,
highly expressed in the aorta but lowly expressed in
other tissues (the Genotype-Tissue Expression
[GTEx] project), in particular EFEMP1, LTBP1, and
MFAP4 (Table 1), into category D (“no evidence”) for
research-based mutation screening in unsolved
HTAAD cases. Moreover, in addition to the clinical
validity of genes and the type/location of sequence
variants, we propose to consider other, less widely
known, challenges/pitfalls in the clinical
interpretation of pathogenicity (2), including
random autosomal monoallelic expression and the
GTEx-based clariﬁcation whether or not the
isoforms expressed in the aorta are indeed affected
(Table 1).
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REPLY: More Genes for Thoracic Aortic
Aneurysms and Dissections
We appreciate the valid comments by Caspar and col-
leagues on our recent paper entitled “Clinical Validity
of Genes for Heritable Thoracic Aortic Aneurysms
and Dissections” (1). Fifty-three potential heritable
thoracic aortic aneurysm and dissection (HTAAD)
genes were curated using a semiquantitative method
developed by ClinGen (2), resulting in 5 categories,
depending on the strength of the gene–disease
relationship, ranging from “deﬁnitive” to “no
evidence.”
Caspar and colleagues suggest adding 3 genes that
were published after our manuscript was submitted.
We agree that these need to be curated. This comment
reﬂects our discussion point that regular and easily
accessible updates of these published data are
required. ClinGen is currently working on a strategy to
implement regular updates of gene–disease curations.
Applying the gene–disease curation matrix reveals
the following results:
TABLE 1 Additional Genes for HTAAD
HGNC Gene Symbol
(Protein Coding Isoform Highly
Expressed in the Aorta*) Gene Function
Median
Expression, TPM*
Reason for Listing
Aortic Disease
Risk as Reported in the
Published Data (Ref. #) Inferred Expression (Tissue)†Aorta Fibroblasts
Genes proposed for the category
“recent genes”
AEBP1 (ENST00000223357,
ENST00000450684)
VSMC differentiation 2,285 118 Recent publication,
highly expressed
in the aorta
1 publication reporting
1 proband with
TAA requiring
surgery (4)
Biallelic (HUVEC)
LMOD1 (ENST00000367288) VSMC contraction 1,114 11 Recent publication,
highly expressed
in the aorta
1 publication reporting
>6 probands with
TAA/AD (3)
Undetermined (HUVEC)
LTBP3 (ENST00000322147) TGF-b sequestration 372 78 Recent publication,
highly expressed
in the aorta
1 publication reporting 7
probands with
TAA/AD (5)
Biallelic (HUVEC)
Genes proposed for the category D
(“no evidence”)
EFEMP1 (ENST00000355426,
ENST00000394555)
ECM component, MMP
regulation, VSMC
homeostasis
1,332 451 Gene function,
highly expressed
in the aorta
No probands with
TAA/AD found
Biallelic (HUVEC)
LTBP1 (ENST00000404525,
ENST00000418533)
TGF-b sequestration 565 229 Gene function,
highly expressed
in the aorta
No probands with
TAA/AD found
Biallelic (HUVEC)
MFAP4 (ENST00000299610) ECM component 1,757 198 Gene function, highly
expressed in the
aorta
No probands with
TAA/AD found
Monoallelic (murine heart;
no data in human tissue)
*According to the Genotype-Tissue Expression (GTEx) project. †According to dbMAE: the database of autosomal monoallelic expression.
AD ¼ aortic dissection; ECM ¼ extracellular matrix; HTAAD ¼ Heritable Thoracic Aortic Aneurysms and Dissections; HUVEC ¼ human vascular epithelium cell lines; MMP ¼ matrix met-
alloproteinase; TAA ¼ thoracic aortic aneurysm; TGF-b ¼ transforming growth factor b; TPM ¼ transcripts per million; VSMC ¼ vascular smooth muscle cell.
J A C C V O L . 7 3 , N O . 4 , 2 0 1 9 Letters
F E B R U A R Y 5 , 2 0 1 9 : 5 2 5 – 3 4
529
